Pull to refresh
Logo
What Changed
Following Why Sign Up
Roche bets $15 billion on Chinese antibody-drug conjugates

Roche bets $15 billion on Chinese antibody-drug conjugates

Money Moves

Hansoh deal is Roche's sixth China pact since late August as it rebuilds its cancer pipeline

October 19th, 2026: Roche and Hansoh announce $15 billion-plus ADC pact

Overview

Updated Oct 30

Roche agreed on Oct. 19 to pay Hansoh Pharmaceutical $400 million upfront, plus $110 million a year later, for a portfolio of antibody-drug conjugates: cancer drugs that carry a toxin straight to tumor cells. Hansoh could collect more than $15 billion in milestones if the programs clear development, regulatory and sales hurdles.

The portfolio holds two preclinical Hansoh candidates and other programs built on targets Roche chose, all using Hansoh's ADC technology. Hansoh runs early testing through Phase Ia trials, then hands worldwide rights outside Greater China to Roche. The targets are undisclosed and nothing has entered human testing, so none of the milestone money is assured.

Why it matters

Roche is buying early-stage Chinese cancer drugs to refill a pipeline as older oncology products lose ground to rivals.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

$15B+
Milestones if the programs succeed
Both companies describe the milestone total as more than $15 billion, paid on development, regulatory and sales benchmarks, plus tiered royalties.
$510M
Guaranteed first-year payments
$400 million upfront plus $110 million due on the deal's first anniversary.
6
Roche China deals since late August
The Hansoh pact is the sixth, a faster pace than any pharmaceutical peer this year, per BioPharma Dive.
2
Preclinical Hansoh candidates in the portfolio
Neither has entered human testing; the other programs are still to be built against Roche-chosen targets.
2
Programs Hansoh may co-fund
Hansoh can contribute to development of up to two programs outside Greater China for extra US commercialization upside.

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

Boris L. Zaïtra
Boris L. Zaïtra
Head of Corporate Business Development at Roche
Led negotiation of the Hansoh collaboration
WS
Weiyong Sun
Chief Business Officer, Hansoh Pharmaceutical Group
Said the Roche pact fits a strategy of taking on more development risk for more future profit

Organizations Involved

Roche / Genentech
Roche / Genentech
Pharmaceutical and diagnostics company
Licensor and payer in the Hansoh deal; expanding ADC pipeline via China partnerships

Swiss drugmaker paying $400 million upfront, plus $110 million a year later, for rights to Hansoh's antibody-drug conjugate portfolio, with more than $15 billion in milestones at stake.
Hansoh Pharmaceutical Group
Hansoh Pharmaceutical Group
Chinese pharmaceutical company
Licensor; running early development through Phase Ia and weighing a co-funding option on two programs

Jiangsu-based drugmaker behind the ADC programs Roche licensed, listed on the Hong Kong Stock Exchange.

Timeline

October 2025 October 2026

5 events Latest: October 19th, 2026 · 3 weeks ago
Tap a bar to jump to that date

  1. Roche and Hansoh announce $15 billion-plus ADC pact

    Latest Deal

    $400 million upfront, $110 million anniversary payment and more than $15 billion in milestones for a broad ADC portfolio, including two preclinical Hansoh candidates.

  2. Roche partners with DualityBio on ADCs

    Deal

    Agreement for next-generation antibody-drug conjugates for patients who progressed after treatment.

  3. Roche's China deal surge begins

    Trend

    Run of Chinese licensing pacts begins, reaching six deals by mid-October.

  4. Roche signs ADC deal with MediLink

    Deal

    Licensing agreement covers an antibody-drug conjugate targeting several solid tumor types.

  5. Roche licenses first Hansoh ADC

    Deal

    Roche pays $80 million upfront, up to $1.45 billion in milestones, for ex-China rights to HS-20110.

Scenarios

1

Roche's ADC gamble lands a late-stage drug

Possible Resolves by Oct 19, 2028

Discussed by: BioPharma Dive and Fierce Biotech deal coverage

If the preclinical candidates produce solid data, several will move through Phase Ia under Hansoh, then into Roche's global development operation. The first visible signs would be trial registrations and early clinical readouts over the next two years.

2

Early failures shrink the $15 billion payday

Possible Resolves by Oct 19, 2028

Discussed by: Clinical trial base rates cited across oncology reporting

Most preclinical antibody-drug conjugates fail in early testing. If the lead programs stall, Hansoh keeps the guaranteed first-year payments but collects few of the milestone payments, which only arrive on development and approval benchmarks.

3

Roche and Hansoh expand to a third alliance

Possible Resolves by Oct 19, 2028

Discussed by: Fierce Biotech, noting the deal builds on the earlier HS-20110 pact

The current pact grew directly out of the first Hansoh collaboration. If early data look strong, the two companies could broaden the relationship further, matching the pattern of repeated, expanding deals.

4

Hansoh buys into the upside on two programs

Possible Resolves by Oct 19, 2028

Discussed by: Hansoh chief business officer Weiyong Sun, in comments to BioCentury

The agreement lets Hansoh put money into developing up to two programs outside Greater China and collect extra US commercialization upside in return. Sun framed the option as part of a shift from straight licensing toward sharing clinical risk for a larger slice of future profits.

5

A rival ADC reaches the market first

Likely Resolves by Jun 15, 2027

Discussed by: Visiongain's Oct. 28 analysis of the ADC investment race

Roche's licensed candidates are preclinical, while competitors are further along. At ESMO in Madrid, MSD and Kelun-Biotech reported a 6.9-month gain in median overall survival with sacituzumab tirumotecan in advanced endometrial cancer, and the FDA set a priority-review decision date of June 15, 2027. AstraZeneca and Daiichi Sankyo also won EU approval for Enhertu in early breast cancer, putting it against Roche's Kadcyla. Earlier rivals reaching patients narrow the commercial room for whatever Roche gets from Hansoh.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

March 2019

AstraZeneca licenses Enhertu from Daiichi Sankyo (2019)

AstraZeneca paid $1.35 billion upfront plus milestone payments for rights to Enhertu, an antibody-drug conjugate, in markets outside Japan. The drug was later approved for several cancers and became one of the world's top-selling oncology treatments.

Then

Enhertu generated billions in annual sales and became a cornerstone of AstraZeneca's oncology line.

Now

The deal set the template for big upfront-plus-milestone ADC licensing arrangements across the industry.

Why this matters now

The structure of Roche's Hansoh deal—large upfront payment, milestone-loaded—mirrors the Enhertu model, the industry's proof that licensed ADCs can become blockbusters.

December 2023

Pfizer acquires Seagen (2023)

Pfizer agreed to buy Seagen for $43 billion, one of the largest biotech acquisitions ever, to gain its antibody-drug conjugate pipeline anchored by the blood cancer drug Adcetris.

Then

The deal closed in December 2023, giving Pfizer one of the largest ADC pipelines in the industry.

Now

It helped trigger a wave of ADC acquisitions and licensing as drugmakers paid premiums for the technology.

Why this matters now

Shows how far drugmakers will go for ADC capability and explains why Roche is committing billions rather than building the technology internally.

Sources

(11)
+5
BioPharma Dive Hansoh Pharmaceutical Group Fierce Biotech eMarketer The Wall Street Journal BioCentury Visiongain OrientSciences News BioXconomy Drugdu BioWorld